{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:59:17Z","timestamp":1788260357278,"version":"build-2803163510"},"reference-count":39,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2024,12,14]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases. By selectively depleting CD19-positive B-cells, this therapy brings a new approach in resetting immune dysregulation and potentially providing long-term remission for patients with a refractory disease. Recent reports have highlighted its effectiveness in conditions such as SLE, systemic sclerosis and myositis. However, while these early results are encouraging, questions remain regarding strategies for optimal patient selection and minimising toxicity on the short and long term. The experiences with CD19 CAR T-cell therapy in haematology may offer valuable insights for immunologists and rheumatologists. This article reviews the key principles learnt in haematology, the results and the mechanisms behind its efficacy, toxicities, and the challenges that need to be addressed for its broader application in clinical practice.<\/jats:p>","DOI":"10.1136\/lupus-2024-001157","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T01:15:35Z","timestamp":1737335735000},"page":"e001157","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?"],"prefix":"10.1136","volume":"12","author":[{"given":"Maria Theresa","family":"Kuipers","sequence":"first","affiliation":[{"name":"Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-2316","authenticated-orcid":false,"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[{"name":"Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands"},{"name":"Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"LYMMCARE Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,19]]},"reference":[{"key":"2025091511252238000_12.1.e001157.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"2025091511252238000_12.1.e001157.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"2025091511252238000_12.1.e001157.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"2025091511252238000_12.1.e001157.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104"},{"key":"2025091511252238000_12.1.e001157.5","doi-asserted-by":"crossref","unstructured":"Jacobson C , Locke FL , Ghobadi A , et al . Long-Term (\u22654 Year and \u22655 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL). Blood 2021;138. doi:10.1182\/blood-2021-148078","DOI":"10.1182\/blood-2021-148078"},{"key":"2025091511252238000_12.1.e001157.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2025091511252238000_12.1.e001157.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00642"},{"key":"2025091511252238000_12.1.e001157.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"2025091511252238000_12.1.e001157.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0"},{"key":"2025091511252238000_12.1.e001157.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"2025091511252238000_12.1.e001157.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5"},{"key":"2025091511252238000_12.1.e001157.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917"},{"key":"2025091511252238000_12.1.e001157.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"2025091511252238000_12.1.e001157.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"2025091511252238000_12.1.e001157.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01969-y"},{"key":"2025091511252238000_12.1.e001157.16","doi-asserted-by":"crossref","unstructured":"Moretti A , Ponzo M , Nicolette CA , et al . The Past, Present, and Future of Non-Viral CAR T Cells. Front Immunol 2022;13. doi:10.3389\/fimmu.2022.867013","DOI":"10.3389\/fimmu.2022.867013"},{"key":"2025091511252238000_12.1.e001157.17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153"},{"key":"2025091511252238000_12.1.e001157.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.003"},{"key":"2025091511252238000_12.1.e001157.19","doi-asserted-by":"crossref","unstructured":"Greco R , Alexander T , Del Papa N , et al . Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. EClinMed 2024;69. doi:10.1016\/j.eclinm.2024.102476","DOI":"10.1016\/j.eclinm.2024.102476"},{"key":"2025091511252238000_12.1.e001157.20","doi-asserted-by":"crossref","unstructured":"Spanjaart AM , Pennings ERA , Mutsaers P , et al . The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands. Cancers 2023;15. doi:10.3390\/cancers15174334","DOI":"10.3390\/cancers15174334"},{"key":"2025091511252238000_12.1.e001157.21","doi-asserted-by":"crossref","unstructured":"Kr\u00f6ger N , Gribben J , Chabannon C , et al , eds. The EBMT\/EHA CAR-T cell handbook. Cham (CH): Springer, 2022.","DOI":"10.1007\/978-3-030-94353-0"},{"key":"2025091511252238000_12.1.e001157.22","doi-asserted-by":"crossref","unstructured":"Lickefett B , Chu L , Ortiz-Maldonado V , et al . Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front Immunol 2023;14. doi:10.3389\/fimmu.2023.1303935","DOI":"10.3389\/fimmu.2023.1303935"},{"key":"2025091511252238000_12.1.e001157.23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jtct.2023.11.008","article-title":"Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Oluwole","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2025091511252238000_12.1.e001157.24","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jtct.2024.01.074","article-title":"Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis","volume":"30","author":"Gagelmann","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2025091511252238000_12.1.e001157.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00547-6"},{"key":"2025091511252238000_12.1.e001157.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2025091511252238000_12.1.e001157.27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017414"},{"key":"2025091511252238000_12.1.e001157.28","first-page":"2443","article-title":"How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity","volume":"141","author":"Santomasso","year":"2023","journal-title":"Blood"},{"key":"2025091511252238000_12.1.e001157.29","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17673"},{"key":"2025091511252238000_12.1.e001157.30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010543"},{"key":"2025091511252238000_12.1.e001157.31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578"},{"key":"2025091511252238000_12.1.e001157.32","doi-asserted-by":"crossref","unstructured":"Kampouri E , Little JS , Rejeski K , et al . Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies. Transpl Infect Dis 2023;25. doi:10.1111\/tid.14157","DOI":"10.1111\/tid.14157"},{"key":"2025091511252238000_12.1.e001157.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104134"},{"key":"2025091511252238000_12.1.e001157.34","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"N Med"},{"key":"2025091511252238000_12.1.e001157.35","doi-asserted-by":"crossref","unstructured":"Reynolds G , Hall VG , Teh BW . Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy. Transpl Infect Dis 2023;25. doi:10.1111\/tid.14109","DOI":"10.1111\/tid.14109"},{"key":"2025091511252238000_12.1.e001157.36","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat Med"},{"key":"2025091511252238000_12.1.e001157.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02826-w"},{"key":"2025091511252238000_12.1.e001157.38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024166"},{"key":"2025091511252238000_12.1.e001157.39","unstructured":"European Medicines Agency . Meeting highlights from the pharmacovigilance risk assessment committee (PRAC) 10-13 June 2024."}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2024-001157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T18:25:30Z","timestamp":1757960730000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2024-001157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,19]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/lupus-2024-001157"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2024-001157","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}